The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)
Objective: To assess the efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in adult patients with moderate COVID-19 symptoms (hospitalized patients with COVID-19 pneumonia who were not admitted to an intensive care unit). Methods: We conducted a randomized, double blind, placebo-controlled,...
Main Authors: | M.Al Ghobain, F. Rebh, A. Saad, A.H. Khan, N. Mehyar, A. Mashhour, I. Islam, Y. Alobaida, A.S. Alaskar, M. Boudjelal, M.Al Jeraisy |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Journal of Infection and Public Health |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034122003094 |
Similar Items
-
The Preventive Effect of Topical Zafirlukast Instillation for Peri-Implant Capsule Formation in Rabbits
by: Shin Hyuk Kang, et al.
Published: (2015-03-01) -
Effects of Zafirlukast on the Capsular Fibrosis of Silicone Breast Implants
by: Emre Hocaoglu, et al.
Published: (2014-06-01) -
Validated stability-indicating methods for the determination of zafirlukast in the presence of its alkaline hydrolysis degradation product
by: Amal M. Abou Al Alamein
Published: (2012-12-01) -
Blockade of Platelet CysLT1R Receptor with Zafirlukast Counteracts Platelet Protumoral Action and Prevents Breast Cancer Metastasis to Bone and Lung
by: Lou Saier, et al.
Published: (2022-10-01) -
Cysteinyl Leukotriene Pathway and Cancer
by: Ming-Ju Tsai, et al.
Published: (2021-12-01)